Watch for effectiveness of the Blank Check Amendment and Series A Preferred Stock filing, which triggers mandatory conversion of May 2026 Notes. The compounding 10% dividend on preferred stock and variable conversion price create a death-spiral dynamic—lower stock prices increase dilution, which further depresses prices. Monitor Nasdaq compliance deadline of Oct 12, 2026 for stockholders' equity requirement.
Executive Summary
DataMeds AI, Inc. filed an S-1/A registration statement for the resale of up to 34,462,057 shares of common stock by selling stockholders, primarily related to convertible notes and warrants issued in May 2026. The company is not selling shares in this offering and will not receive proceeds from share sales, though it may receive proceeds from cash exercise of warrants. The filing highlights massive potential dilution: at a $1.00 conversion price, existing stockholders would hold only 8.8% of the post-conversion/exercise float, and the company faces ongoing Nasdaq compliance risk for minimum stockholders' equity.
Key Facts
- Up to 34,462,057 shares registered for resale vs. 4,515,862 shares outstanding as of Sept 28, 2026.
- At $1.00 conversion price, existing stockholders would hold ~8.8% of post-conversion/exercise shares.
- May 2026 Notes have $21.3M principal, convertible at variable price with $1.00 floor; PIPE Warrants exercisable at $7.50.
- Series A Preferred Stock accrues 10% dividends added to stated value, compounding dilution.
- Company received Nasdaq deficiency notice for minimum stockholders' equity ($2.5M) in April 2026; compliance deadline Oct 12, 2026.
- Stock closed at $2.88 on Oct 7, 2026; recent trading range $0.85-$6.07.
- Helomics acquisition closed Sept 11, 2026 for 636,328 shares + $1.36M convertible note.
- Company changed name from Wellgistics Health to DataMeds AI and ticker from WGRX to MEDS in July 2026.
Financial Impact
Potential dilution of 55.1% to 1,800%+ depending on conversion price; existing holders could see ownership reduced to 5.3%-19.4%
Risk Factors
- Massive dilution from convertible notes and warrants could overwhelm existing shareholders
- Death-spiral conversion structure: lower stock price → more shares issued → further price decline
- Nasdaq delisting risk if stockholders' equity compliance not demonstrated by Oct 12, 2026
- Company has no revenue visibility in filing; prior to acquisitions, it generated no revenue
- Multiple pending transactions (Healthstar, EOS/Scilex/Datavault) add execution uncertainty
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-046608 |
| Exhibit: ex23-1.htm | 0001493152-26-046608 |
| Document: 0001493152-26-046608-index-headers.html | 0001493152-26-046608 |
| Document: 0001493152-26-046608-index.html | 0001493152-26-046608 |
| Document: 0001493152-26-046608.txt | 0001493152-26-046608 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | S-1/A | — | awaiting T+20 | — | — |
May 29, 2026 21w ago | 8-K | $3.85 $3.10 | ▲ +19.48% | ▲ +18.18% | — |
May 21, 2026 22w ago | 8-K | $5.35 $3.18 | ▼ −40.52% | ▼ −40.85% | — |
May 19, 2026 22w ago | 8-K | $6.45 $3.39 | ▼ −47.44% | ▼ −48.18% | — |
May 19, 2026 22w ago | 8-K | $8.40 $3.70 | ▼ −55.95% | ▼ −56.94% | — |
May 18, 2026 23w ago | 8-K | $8.70 $3.69 | ▼ −57.59% | ▼ −59.17% | — |
May 8, 2026 24w ago | EFFECT | $4.21 $4.35 | ▼ −3.33% | ▼ −3.30% | — |
Apr 24, 2026 26w ago | 10-K/A | $6.23 $3.82 | ▲ +38.68% | ▲ +43.64% | — |
Apr 17, 2026 27w ago | 8-K | $6.60 $8.70 | ▲ +31.82% | ▲ +27.62% | — |
Apr 15, 2026 27w ago | S-3 | $7.37 $4.70 | ▼ −36.18% | ▼ −42.82% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers